References of "European Heart Journal"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailBenefit of revascularization for stable ischaemic heart disease: the jury is still out.
Fassa, Amir-Ali; Wijns, William; Kolh, Philippe ULiege et al

in European Heart Journal (2013), 34(21), 1534-8

Detailed reference viewed: 20 (0 ULiège)
Full Text
Peer Reviewed
See detailLeft ventricular contractile reserve in asymptomatic primary mitral regurgitation
Magne, Julien ULiege; Mahjoub, H; PIERARD, Luc ULiege et al

in European Heart Journal (2013)

Detailed reference viewed: 44 (7 ULiège)
Full Text
Peer Reviewed
See detailTricuspid valve regurgitation in patients with heart failure: does it matter?
Lancellotti, Patrizio ULiege; Magne, Julien ULiege

in European Heart Journal (2013)

Detailed reference viewed: 39 (4 ULiège)
Full Text
Peer Reviewed
See detailGuidelines on the management of valvular heart disease (version 2012).
Vahanian, Alec; Alfieri, Ottavio; Andreotti, Felicita et al

in European Heart Journal (2012), 33(19), 2451-96

Detailed reference viewed: 30 (1 ULiège)
Full Text
Peer Reviewed
See detailThird universal definition of myocardial infarction.
Thygesen, Kristian; Alpert, Joseph S.; Jaffe, Allan S. et al

in European Heart Journal (2012), 33(20), 2551-67

Detailed reference viewed: 410 (0 ULiège)
Full Text
Peer Reviewed
See detailESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
Steg, Ph Gabriel; James, Stefan K.; Atar, Dan et al

in European Heart Journal (2012), 33(20), 2569-619

Detailed reference viewed: 65 (5 ULiège)
Full Text
Peer Reviewed
See detailESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
Reiner, Zeljko; Catapano, Alberico L; De Backer, Guy et al

in European Heart Journal (2011), 32(14), 1769-818

Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and ... [more ▼]

Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and is also increasingly common in developing countries.1 In the European Union, the economic cost of CVD represents annually E192 billion1 in direct and indirect healthcare costs. The main clinical entities are coronary artery disease (CAD), ischaemic stroke, and peripheral arterial disease (PAD). The causes of these CVDs are multifactorial. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidaemias, or non-modifiable, such as age and male gender. These guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. Prevention and treatment of dyslipidaemias should always be considered within the broader framework of CVD prevention, which is addressed in guidelines of the Joint European Societies' Task forces on CVD prevention in clinical practice.2 - 5 The latest version of these guidelines was published in 20075; an update will become available in 2012. These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians [e.g. general practitioners (GPs) and cardiologists] interested in CVD prevention, but also specialists from lipid clinics or metabolic units who are dealing with dyslipidaemias that are more difficult to classify and treat. [less ▲]

Detailed reference viewed: 1070 (3 ULiège)
Full Text
Peer Reviewed
See detailESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).
Regitz-Zagrosek, Vera; Blomstrom Lundqvist, Carina; Borghi, Claudio et al

in European Heart Journal (2011), 32(24), 3147-97

Detailed reference viewed: 1258 (2 ULiège)
Full Text
Peer Reviewed
See detailA moving heart
Moonen, Marie ULiege; Davin, Laurent ULiege; Lancellotti, Patrizio ULiege et al

in European Heart Journal (2010)

Detailed reference viewed: 47 (10 ULiège)
Full Text
Peer Reviewed
See detailGuidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
Camm, A John; Kirchhof, Paulus; Lip, Gregory Y H et al

in European Heart Journal (2010), 31(19), 2369-429

Detailed reference viewed: 2959 (0 ULiège)
Full Text
Peer Reviewed
See detailIschaemic mitral regurgitation: pathophysiology, outcomes and the conundrum of treatment.
PIERARD, Luc ULiege; Carabello, B. A.

in European Heart Journal (2010), 31

Ischaemic mitral regurgitation is a frequent complication of left ventricular global or regional pathological remodelling due to chronic coronary artery disease. It is not a valve disease but represents ... [more ▼]

Ischaemic mitral regurgitation is a frequent complication of left ventricular global or regional pathological remodelling due to chronic coronary artery disease. It is not a valve disease but represents the valvular consequences of increased tethering forces (papillary muscles displacement leading to a more apical position of the leaflets and their coaptation point) and reduced closing forces (reduced contractility, dyssynchrony of the papillary muscles, intra-left ventricular dyssynchrony). Although mitral regurgitation has an unloading effect and reduces impedance, the volume overload begets further left ventricular dilatation, increases ventricular wall stress leading to worsened performance. Ischaemic mitral regurgitation is characteristically dynamic: its severity may vary with haemodynamic conditions. Both the severity of ischaemic mitral regurgitation and its dynamic component worsen prognosis. There are numerous possible treatment modalities, but the management of the individual patient remains difficult. Medical therapy is mandatory; revascularization procedures are frequently not sufficient to reduce mitral regurgitation; the role of combined surgical therapy by mitral valve repair is not yet defined in the absence of large randomized trial. Some patients are good candidates for cardiac resynchronization therapy that may reduce the amount of regurgitation. New therapeutic targets are under investigation. [less ▲]

Detailed reference viewed: 83 (2 ULiège)
Full Text
Peer Reviewed
See detailExperience with revascularization procedures does matter: low volume means worse outcome.
Wijns, William; Kolh, Philippe ULiege

in European Heart Journal (2010), 31(16), 1954-7

Detailed reference viewed: 19 (1 ULiège)